structural heart device company. The proposed transaction signals Alkem’s strategic push into the global minimally invasive cardiac implant market.

Transaction Details

Under the proposed agreement, Alkem MedTech plans to acquire up to a 55% stake in Occlutech for €99.4 million (approximately ₹1,074 crore).

Occlutech specialises in minimally invasive cardiac implants and has built a strong footprint across key international markets, particularly in Europe and the United States.

Operational Footprint of Occlutech

• Manufacturing and R&D facilities: Germany and Turkey
• Global distribution centre: Sweden
• Clinical operations: United States

For calendar year 2025, Occlutech reported revenue of €49.4 million, reflecting a three-year compound annual growth rate (CAGR) of 15.7%. Nearly 85% of its revenue is derived from Europe and US markets, underlining its strong presence in developed healthcare systems.

Strategic Rationale

The acquisition is positioned as a pivotal step in Alkem MedTech’s ambition to expand into high-value, technology-driven medical devices.

According to company filings, Alkem’s leadership highlighted that the transaction aligns with the group’s broader objective of building a global footprint in medical technology—mirroring its established success in the pharmaceutical sector.

Occlutech brings established expertise in structural heart devices, along with advanced R&D capabilities, manufacturing infrastructure, and a strong regulatory and quality compliance framework. These capabilities are expected to provide a robust platform for Alkem MedTech to scale its presence in the cardiology space.

Market Access and Growth Outlook

Through this proposed majority acquisition, Alkem MedTech gains entry into high-entry-barrier cardiovascular device markets, including:

• United States
• Japan
• Major Western European countries

The transaction is expected to accelerate the company’s global expansion strategy and strengthen its positioning in advanced, innovation-led medical technology segments.

By leveraging Occlutech’s existing product portfolio and regulatory approvals, Alkem MedTech could fast-track its participation in the rapidly growing structural heart device market.

Summary

Alkem MedTech has submitted a binding offer to acquire up to 55% stake in Switzerland-based Occlutech Holding AG for €99.4 million (around ₹1,074 crore). Occlutech, which specialises in minimally invasive cardiac implants, reported €49.4 million in revenue in 2025 with strong growth momentum and significant exposure to Europe and the US. The proposed acquisition strengthens Alkem’s global medical devices ambitions and provides entry into high-barrier cardiovascular markets, supporting its long-term international expansion strategy.

This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.

Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.